Evaluation of the BOKS Before-school Physical Activity Program

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03190135
Collaborator
Reeboks BOKS (Other)
1,250
3
3
9
416.7
46.5

Study Details

Study Description

Brief Summary

BOKS, Build Our Kids' Success, is a before-school physical activity program that has been implemented in over 2,000 elementary and middle schools. Students participate in the program for 12 weeks, two or three mornings per week for about 1 hour per session. This study if a non-randomized control trial seeking to 1) examine the extent to which participation in the before-school BOKS program improves, health, well-being, and performance, and 2) compare the results of a two-day-per-week versus a three-day-per-week program.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: BOKS: 2 day a week before-school physical activity program
  • Behavioral: BOKS: 3 day a week before-school physical activity program
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1250 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Evaluation of the Build Our Kids' Success (BOKS) Before-school Physical Activity Program
Actual Study Start Date :
Sep 1, 2015
Actual Primary Completion Date :
May 31, 2016
Actual Study Completion Date :
May 31, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: BOKS: 2 day per week

Behavioral: BOKS: 2 day a week before-school physical activity program
Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.

Experimental: BOKS: 3 day per week

Behavioral: BOKS: 3 day a week before-school physical activity program
Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.

No Intervention: Non-BOKS

Outcome Measures

Primary Outcome Measures

  1. Change from baseline Body Mass Index at 12 weeks [baseline, 12 weeks]

    Body Mass Index (kg/m^2): calculated from height and weight

  2. Change from baseline Body Mass Index Z-score at 12 weeks [baseline, 12 weeks]

    Age- and sex- specific Body Mass Index Z-score

Secondary Outcome Measures

  1. Change from baseline 400 meter run time at 12 weeks [baseline, 12 weeks]

    Time (seconds) to complete a 400 meter run

  2. Change from baseline physical activity at 12 weeks [baseline, 12 weeks]

    Days per week of physical activity

  3. Change from baseline peer relationships at 12 weeks [baseline, 12 weeks]

    PROMIS validated scale

  4. Change from baseline positive affect at 12 weeks [baseline, 12 weeks]

    PROMIS validated scale

  5. Change from baseline life satisfaction at 12 weeks [baseline, 12 weeks]

    PROMIS validated scale

  6. Change from baseline vitality/energy at 12 weeks [baseline, 12 weeks]

    Healthy Pathways Child-Report Scales

  7. Change from baseline student engagement at 12 weeks [baseline, 12 weeks]

    Healthy Pathways Child-Report Scales

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 14 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Participating school

  • Child age 5-14 years

Exclusion Criteria:
  • No valid parental consent

  • Missing group assignment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Plymouth Public Schools Plymouth Massachusetts United States 02360
2 Quincy Public Schools Quincy Massachusetts United States 02169
3 Weymouth Public Schools Weymouth Massachusetts United States 02190

Sponsors and Collaborators

  • Massachusetts General Hospital
  • Reeboks BOKS

Investigators

  • Principal Investigator: Elsie Taveras, MD, MPH, Massachusetts General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Elsie Taveras, MD, Chief, Division of General Academic Pediatrics, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT03190135
Other Study ID Numbers:
  • 2017P000177
First Posted:
Jun 16, 2017
Last Update Posted:
Jun 16, 2017
Last Verified:
Jun 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Elsie Taveras, MD, Chief, Division of General Academic Pediatrics, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 16, 2017